The clinical pipeline for Alzheimer’s disease: Data Byte

Product Development

By  selina koch, govt editor, and gunjan ohri, information content material analyst

Mar 16, 2021 | 1:35 AM GMT

Although amyloid-lowering brokers nonetheless symbolize the lion’s share of late-stage candidates for Alzheimer’s illness, they account for lower than 20% of compounds throughout all clinical phases. Tau inhibition, modulation of neurotransmitter signaling, and quelling of neuroinflammation are all mechanisms